Zynerba Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Zynerba Pharmaceuticals generated cash of -$23,026,950, which is more than the previous year. Cash used in financing activities reached the amount of $6,014,048 last year. Net change in cash is therefore -$17,167,007.
Cash Flow
| 2013 | -117.70K | -2.70K | 109.45K |
|---|---|---|---|
| 2014 | -3.54M | -19.71K | 12.73M |
| 2015 | -9.78M | -216.33K | 42.18M |
| 2016 | -20.43M | -109.62K | 10.00M |
| 2017 | -25.84M | -115.35K | 57.50M |
| 2018 | -32.39M | -286.65K | 29.93M |
| 2019 | -34.81M | -129.39K | 45.24M |
| 2020 | -41.31M | -445.31K | 30.85M |
| 2021 | -33.45M | -47.57K | 42.15M |
| 2022 | -23.02M | -154.10K | 6.01M |
ZYNE Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 67.80M | 59.15M | 70.06M | 59.76M | 62.51M | 30.96M | 41.51M | 9.33M | 154.69K | 165.64K |
Operating activities | ||||||||||
Net income | -35.03M | -37.30M | -51.33M | -32.94M | -39.91M | -32.01M | -23.38M | -12.55M | -5.66M | -636.79K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 219.28K | 247.14K | 207.03K | 133.87K | 99.57K | 94.21K | 75.30K | 26.02K | 27.06K | 49.39K |
Stock-based compensation expense | 4.33M | 5.81M | 5.17M | 5.56M | 6.62M | 5.64M | 3.26M | 1.60M | 0 | 0 |
| Deferred income tax benefit | 4.33M | 5.81M | 5.17M | 5.56M | 6.62M | 5.64M | 3.26M | 1.60M | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 70.56K | -723.90K | -2.14M | 209.61K | 1.10M | 1.49M | 1.04M | 536.35K | 140.10K | 86.23K |
Cash generated by operating activities | -23.02M | -33.45M | -41.31M | -34.81M | -32.39M | -25.84M | -20.43M | -9.78M | -3.54M | -117.70K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -154.10K | -47.57K | -445.31K | -129.39K | -286.65K | -115.35K | -109.62K | -216.33K | -19.71K | -2.70K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -154.10K | -47.57K | -445.31K | -129.39K | -286.65K | -115.35K | -109.62K | -216.33K | -19.71K | -2.70K |
Financing activities | ||||||||||
Common Stock Issued | 6.55M | 43.19M | 31.70M | 45.18M | 29.93M | 57.29M | 10.00M | 42.12M | 1.40K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -499.99K | 0 |
Cash used in financing activities | 6.01M | 42.15M | 30.85M | 45.24M | 29.93M | 57.50M | 10.00M | 42.18M | 12.73M | 109.45K |
Net Change In Cash | -17.16M | 8.65M | -10.90M | 10.29M | -2.74M | 31.54M | -10.54M | 32.18M | 9.17M | -10.95K |
Cash at end of period | 50.64M | 67.80M | 59.15M | 70.06M | 59.76M | 62.51M | 30.96M | 41.51M | 9.33M | 154.69K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |